research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
Search
for
Sort by
Research
810-840 / 1000+ results
research A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-l -carnitine to prevent and treat hair loss: A prospective investigation
The lotion with equol, dihomo-γ-linolenic acid, and propionyl-l-carnitine was effective in reducing hair loss in men and women.
research Therapeutic and skincare products used in hirsutism and hypertrichosis
Prescription tablets treat hirsutism, while over-the-counter foams treat hypertrichosis.
research Anti-androgenetic effect of diphlorethohydroxycarmalol on testosterone-induced hair loss by inhibiting 5α-reductase and promoting Wnt/β-catenin signaling pathway in human dermal papilla cells
Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
research Women’s Health Care During the Perimenopause
The document concludes that low-dose oral contraceptives and hormonal therapies can manage perimenopause symptoms and reduce some health risks, but lifestyle changes and disease screening are also important.
research Evaluation of New Pregnane Derivatives as 5.ALPHA.-Reductase Inhibitor.
New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.
research Effective medical treatment for common baldness in women
Antiandrogen therapy helped increase hair growth in women with hormonal imbalances related to baldness.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
research Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility
Lifestyle changes, medications, and fertility treatments can improve PCOS symptoms and prevent complications.
research The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response
Most patients improved with oral contraceptives, but some needed additional treatment.
research REVERSED SEQUENTIAL THERAPY OF HIRSUTISM USING CYPROTERONE ACETATE
Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
research In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research Squalene-Containing Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Diphencyprone for Treating Alopecia Areata
Squalene-based carriers improve delivery of a treatment to hair follicles for alopecia areata.
research Management of adolescent polycystic ovary syndrome
SPIOMET therapy may be a promising alternative to oral contraceptives for treating adolescent PCOS.
research Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Spironolactone and breast cancer: Fear not!
Spironolactone does not increase the risk of breast cancer recurrence.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.
research Brown Adipose Tissue and Novel Management Strategies for Polycystic Ovary Syndrome Therapy
Activating brown fat may help manage PCOS symptoms.
research ROLE OF PLATELET-RICH PLASMA IN ANDROGENETIC ALOPECIA: A PROSPECTIVE STUDY
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
research MON-323 Metastatic Adrenocortical Carcinoma Presenting with Mixed Cushing's and Virilization Syndrome along with Bilateral Pulmonary Emboli
Rapid virilization should be checked for possible ovarian or adrenal cancer.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Severe Hyperandrogenism in A Premenopausal Woman With An Imaging-Negative Leydig Cell Tumor
A woman's severe male hormone excess was caused by a small, hard-to-find ovarian tumor.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.